• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials.

作者信息

Eichacker Peter Q, Natanson Charles

机构信息

Critical Care Medicine Department, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.

出版信息

Crit Care Med. 2003 Jan;31(1 Suppl):S94-6. doi: 10.1097/00003246-200301001-00013.

DOI:10.1097/00003246-200301001-00013
PMID:12544982
Abstract
摘要

相似文献

1
Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials.重组人活化蛋白C用于脓毒症治疗：试验结果不一致、作用机制不明以及安全性问题导致了标签限制和开展IV期试验的必要性。
Crit Care Med. 2003 Jan;31(1 Suppl):S94-6. doi: 10.1097/00003246-200301001-00013.
2
Pharmacology, clinical efficacy, and safety of drotrecogin alfa (activated).重组人活化蛋白C的药理学、临床疗效及安全性
Pharmacotherapy. 2002 Dec;22(12 Pt 2):182S-195S. doi: 10.1592/phco.22.18.182s.33704.
3
Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis.重组人活化蛋白C（活化）用于治疗严重脓毒症。
Crit Care Med. 2003 Jan;31(1 Suppl):S85-93. doi: 10.1097/00003246-200301001-00012.
4
Should we be using activated protein C to treat severe sepsis?我们应该使用活化蛋白C来治疗严重脓毒症吗？
Br J Hosp Med (Lond). 2009 Aug;70(8):484. doi: 10.12968/hmed.2009.70.8.43548.
5
Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial.重新评估重组人活化蛋白C治疗脓毒症：开展新的随机对照试验的时候了。
Crit Care Med. 2005 Oct;33(10):2426-8. doi: 10.1097/01.ccm.0000183002.26587.ff.
6
Risks and benefits of activated protein C treatment for severe sepsis.活化蛋白C治疗严重脓毒症的风险与益处
N Engl J Med. 2002 Sep 26;347(13):1027-30. doi: 10.1056/NEJMsb020574.
7
Clinical trials in severe sepsis with drotrecogin alfa (activated).使用重组人活化蛋白C（drotrecogin alfa）治疗严重脓毒症的临床试验。
Crit Care. 2007;11 Suppl 5(Suppl 5):S5. doi: 10.1186/cc6156.
8
Drotrecogin alfa on trial.活化蛋白C进行试验。
Lancet Infect Dis. 2009 Jan;9(1):2-3. doi: 10.1016/S1473-3099(08)70286-X.
9
Assessing the use of activated protein C in the treatment of severe sepsis.评估活化蛋白C在严重脓毒症治疗中的应用。
N Engl J Med. 2002 Sep 26;347(13):1030-4. doi: 10.1056/NEJMsb021512.
10
Substantiating the concerns about recombinant human activated protein C use in sepsis.证实对重组人活化蛋白C用于脓毒症治疗的担忧。
Crit Care Med. 2004 Dec;32(12):2542-3. doi: 10.1097/01.ccm.0000148090.94378.6a.

引用本文的文献

1
Recombinant human activated protein C for severe sepsis in neonates.重组人活化蛋白C用于新生儿严重脓毒症
Cochrane Database Syst Rev. 2012 Apr 18;2012(4):CD005385. doi: 10.1002/14651858.CD005385.pub3.
2
Results from the National Sepsis Practice Survey: use of drotrecogin α (activated) and other therapeutic decisions.国家脓毒症实践调查结果：使用替考拉宁 α（激活）和其他治疗决策。
J Crit Care. 2010 Dec;25(4):658.e7-15. doi: 10.1016/j.jcrc.2010.04.010. Epub 2010 Jun 19.
3
Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies.
对脓毒症中活化蛋白C给药潜在益处和风险的深入认识：临床前和临床研究综述
Biologics. 2009;3:391-406. doi: 10.2147/btt.2009.3547. Epub 2009 Sep 15.
4
The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis.脓毒症期间使用类固醇的效果取决于剂量和疾病严重程度：一项更新的荟萃分析。
Clin Microbiol Infect. 2009 Apr;15(4):308-18. doi: 10.1111/j.1469-0691.2009.02752.x.
5
Science, medicine and industry: are we getting out of the black hole in sepsis research?科学、医学与产业：我们是否正在走出脓毒症研究的黑洞？
Intensive Care Med. 2008 Nov;34(11):1950-4. doi: 10.1007/s00134-008-1302-6. Epub 2008 Oct 7.
6
Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis.重组人活化蛋白C治疗严重脓毒症：系统评价与新的成本效益分析
BMC Anesthesiol. 2007 Jun 25;7:5. doi: 10.1186/1471-2253-7-5.
7
[Endogenous anticoagulant therapy for sepsis. Success and failure].[脓毒症的内源性抗凝治疗。成功与失败]
Internist (Berl). 2007 May;48(5):537-42, 544. doi: 10.1007/s00108-007-1840-y.
8
Increasing evidence that the risks of rhAPC may outweigh its benefits.越来越多的证据表明，重组人活化蛋白C（rhAPC）的风险可能超过其益处。
Intensive Care Med. 2007 Mar;33(3):396-9. doi: 10.1007/s00134-007-0556-8. Epub 2007 Feb 15.
9
An algorithmic computerised order entry approach to assist in the prescribing of new therapeutic agents: case study of activated protein C at an academic medical centre.一种辅助新型治疗药物处方开具的计算机算法医嘱录入方法：学术医学中心活化蛋白C的案例研究
Drug Saf. 2004;27(15):1253-61. doi: 10.2165/00002018-200427150-00008.
10
Pathogenesis of malaria and clinically similar conditions.疟疾及临床相似病症的发病机制。
Clin Microbiol Rev. 2004 Jul;17(3):509-39, table of contents. doi: 10.1128/CMR.17.3.509-539.2004.